

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	5273-90	Appln. No.	10/647,234
Applicant	Koichiro YAMADA et al.		
Filing Date	August 26, 2003	Group:	Not yet assigned-1629



U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriated
T	6,136,810	24 Oct 2000	Takayama et al.	514	258	
	5,817,670	6 Oct 1998	Takayama et al.	514	300	
	5,733,914	31 Mar 1998	Blankley et al.	514	258	
	5,693,652	2 Dec 1997	Takase et al.	514	322	
	5,466,692	14 Nov 1995	Ellingboe	514	258	
	4,229,456	21 Oct 1980	Bolhofer et al.	424	256	
V	4,060,615	29 Nov 1977	Matier et al.	424	251	

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
h	WO 96/16644	6 June 1996	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>h</i>	Bolhofer, W., et al., "Inhibition of Gastric Acid Secretion by 1,8-Naphthyridin-2(1H)-ones," <i>J. of Med. Chem.</i> , Vol. 22, No. 3, pp. 301-306 (1979).

Examiner <i>John McAlle</i>	Date Considered <i>2/18/05</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 627626_1.DOC	Patent and Trademark Office - U.S. Department of Commerce

## INFORMATION DISCLOSURE CITATION



Atty. Docket No. 5273-90	Serial No. 10/647,234
Applicant Koichiro YAMADA et al.	
Filing Date August 26, 20003	Group: Not yet assigned

## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS


	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP	EP 0722936	24 July 1996	Europe			
✓	AU 199955977 A1	4 May 2000	Australia			
✓	DE 2064 096	6 July 1972	Germany		Abstract	

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	Vermulapalli, S., et al., "Sildenafil relaxes rabbit clitoral corpus cavernosum," <i>Life Sciences</i> , Vol. 67, pp. 23-29 (2000).
	Watkins, C., et al., "Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy," <i>The Journal of Clinical Investigation</i> , Vol. 106, No. 3, pp. 373-384 (2000).
	Bortolotti, M., et al., "Effects of Sildenafil on Esophageal Motility of Patients with Idiopathic Achalasia," <i>Gastroenterology</i> , Vol. 118, pp. 253-257 (2000).
	Mule F., et al., "Tonic Inhibitory action by nitric oxide on spontaneous mechanical activity in rat proximal colon: involvement of cyclic GMP and apamin-sensitive K <sup>+</sup> channels," <i>British Journal of Pharmacology</i> , Vol. 127, pp. 514-520 (1999).
	Turner, N., et al., "Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anesthetized guinea-pig," <i>British Journal of Pharmacology</i> , Vol. 111, pp. 1198-1204 (1994).
	Bakre M., et al., "Expression and Regulation of the cGMP-Binding, cGMP-Specific Phosphodiesterase (PDE5) in Colonic Epithelial Cells: Role in the Induction of Cellular Refractoriness to the Heat-Stable Enterotoxin Peptide," <i>Journal of Cellular Biochemistry</i> , Vol. 77, pp. 159-167 (2000).
✓	Boolell, M., et al., "A new oral treatment for erectile dysfunction. A Double-blind, placebo controlled crossover study demonstrating dose response with rigiscan and efficacy with outpatient diary," <i>The Journal of Urology</i> , Supplement, Vol. 155, No. 5, p. 495A 739 (1996).

*Don McAllister* 2/18/01

## INFORMATION DISCLOSURE CITATION



Atty. Docket No.	5273-90	Serial No.	10/647,234
Applicant	Koichiro YAMADA et al.		
Filing Date	August 26, 20003	Group:	62 (Not yet assigned)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Tar</i>	Terrett, N., et al., "Sildenafil (Viagra™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 6, No. 15, pp. 1819-1824 (1996).
	Ballard, S., et al., "Sildenafil, a potent selective inhibitor of type 5 phosphodiesterase, enhances nitric oxide-dependent relaxation of rabbit corpus cavernosum," <i>British Journal of Pharmacology, Proceedings Supplement</i> , Vol. 118, 153P (1996).
	Goldstein, I., et al., "Oral sildenafil in the treatment of erectile dysfunction," <i>The New England Journal of Medicine</i> , Vol. 338, No. 20, p. 1397-1404 (1998).
	Goldenberg, M., "Safety and Efficacy of Sildenafil Citrate in the Treatment of Male Erectile Dysfunction," <i>Clinical Therapeutics</i> , Vol. 20, No. 6, pp. 1033-1048 (1998).
	Morales, A., et al., "Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction," <i>International Journal of Impotence Research</i> , Vol. 10, No. 2, pp. 69-73 (1998).
	Estrade, M., et al., "Effect of a cGMP-specific phosphodiesterase inhibitor on retinal function," <i>European Journal of Pharmacology</i> , Vol. 352, pp. 157-163 (1998).
	Todd, C., et al., "Sulfilimines Derived from Sulfanilamide," <i>Journal of American Chemical Society</i> , Vol. 65, pp. 350-355 (1943).
	Grohe, K., et al., "Synthese und Reaktionen von 2,4-Dichlorpyrimidin-5-carbon-saureestern," <i>Liebigs Ann. Chem.</i> , pp. 1025-1035 (1973).

Examiner	<i>Don McPh</i>	Date Considered	<i>3/16/05</i>
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO-1449	Patent and Trademark Office - U.S. Department of Commerce		

628022\_1